Amgen is expanding development plans for its weight-loss drug MariTide to study its use for heart disease and sleep apnea. In a phase 2 trial, the drug demonstrated 20% average weight loss among ...

Amgen announced detailed tolerability data from phase 1 and phase 2 studies of obesity drug candidate maritide, and management disclosed the design of its two ongoing phase 3 obesity studies.

Amgen's (AMGN) late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls patients in its phase 3 trial.

MariTide researchers said gastrointestinal issues were “common” with the drug, but the drug's side effects are similar to those of other GLP-1 medications. They include nausea, abdominal pain ...

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new GLP-1 hits the market.

In the Phase 2 study, patients with obesity taking the injectable drug, called MariTide, lost up to 16.2% of their weight in one year when taking into account all participants regardless of ...

MariTide is the First Monthly or Less Frequently Dosed Peptide-Antibody Conjugate Being Investigated for the Treatment of Obesity and Type 2 Diabetes New Repatha® Data Provide Insight Into the ...

Investing.com - TD Cowen has reiterated its Buy rating and $389.00 price target on Amgen (NASDAQ: AMGN) stock, highlighting the potential of the company’s Maritide drug candidate. The research firm ...

--Amgen today announced full results from Part 1 of the Phase 2 study for MariTide in patients living with obesity, with and without Type 2 diabetes, will be presented along with new data from the ...

Beyond MariTide, Amgen’s pipeline includes several other promising candidates. Imdelltra, a DLL3 targeting drug for oncology, has shown rapid growth and potential for near-term upside.

MariTide (maridebart cafraglutide; previously AMG 133) has emerged as one of Amgen's most promising pipeline projects thanks to its potential to offer once-monthly or even less frequent dosing, in ...